{"url_path":"/sec/gri/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1824293/0001824293-26-000046-index.html","accession_number":"0001824293-26-000046","cik":"0001824293","ticker":"GRI","issuer_name":"GRI Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1824293/0001824293-26-000046-index.html","primary_entity_key":"0001824293","primary_entity_name":"GRI Bio, Inc."},"word_count":191,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\nOn May 14, 2026, GRI Bio, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the three months ended March 31, 2026 and summarizing key recent highlights. A copy of the Press Release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information in this Item 2.02 and Exhibit 99.1 is being furnished and, except as otherwise set forth in this Current Report on Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying Exhibit 99.1 shall not be deemed, except as otherwise set forth in this Current Report on Form 8-K, incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof regardless of any general incorporation language in such filing."}